> Back to EJC


Previous editions of EJC News Focus

  • November 2011
    Gordon Mills assesses the challenges we face in developing personalised medicine.
  • October 2011
    Richard Sullivan explains why the spiralling rise in healthcare costs associated with cancer is unsustainable.
  • September 2011
    Anne-Lise Borresen-Dale discusses key themes to emerge at the European Multidisciplinary Cancer Congress in Stockholm.
  • August 2011
    Jean-Charles Soria, EJC's Drug Development Editor, on the need for a new consensus on assessing toxicities.
  • July 2011
    EJC editor-in-chief Alexander Eggermont on recent advances in melanoma treatment.
  • June 2011
    Jean-Yves Blay discusses how EORTC is adapting to the new environment for research.
  • April/May 2011
    Cora Sternberg reveals exciting developments in the treatment of prostate cancer.
  • March 2011
    EJC's editor for gastrointestinal cancers, Eric van Cutsem, discusses the disappointing findings of recent trials of bevacizumab in colon cancer
  • February 2011
    Michel Coleman from the London School of Hygiene and Tropical Medicine discusses a comparison of cancer survival rates in different countries.
  • January 2011
    Jan Willem Coebergh discusses a paper relating to the NELSON lung cancer trial.

EJC News Focus – April/May 2011

Loading EJC News Focus video


In this edition of EJC News Focus, Helen Saul discusses exciting developments in the treatment of castration-resistant prostate cancer* with EJC’s editor for genitourinary cancers, Cora Sternberg (San Camillo and Forlanini Hospitals, Rome, Italy).


* Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel-based chemotherapy. Presented at ASCO GU, 2011 by Howard Scher, Abstract #4.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Johann Sebastian de Bono et al, Lancet 2010; 376: 1147-54

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Karim Fizazi et al, Lancet 2011; 377: 813-822

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Philip Kantoff et al, N Engl J Med 2010; 363: 411-422